- Home
- UNH vs ABBV Comparison
UNH vs ABBV Comparison
Compare UNH & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UNH | ABBV |
|---|---|---|
| Founded | 1977 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.3B | 375.7B |
| IPO Year | 2010 | 2012 |
Fundamental Metrics
Financial Performance| Metric | UNH | ABBV |
|---|---|---|
| Price | $316.39 | $209.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 19 |
| Target Price | ★ $377.83 | $250.56 |
| AVG Volume (30 Days) | ★ 6.8M | 4.7M |
| Earning Date | 04-21-2026 | 04-29-2026 |
| Dividend Yield | 2.81% | ★ 3.32% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 13.23 | 2.36 |
| Revenue | ★ $447,567,000,000.00 | $61,160,000,000.00 |
| Revenue This Year | N/A | $11.90 |
| Revenue Next Year | $3.25 | $8.13 |
| P/E Ratio | ★ $23.78 | $88.41 |
| Revenue Growth | ★ 11.81 | 8.57 |
| 52 Week Low | $234.60 | $168.54 |
| 52 Week High | $453.50 | $244.81 |
Technical Indicators
Market Signals| Indicator | UNH | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 69.70 | 44.42 |
| Support Level | $304.53 | $204.17 |
| Resistance Level | $316.40 | $212.45 |
| Average True Range (ATR) | 7.44 | 5.11 |
| MACD | 4.53 | 0.43 |
| Stochastic Oscillator | 94.93 | 39.37 |
Price Performance
Historical ComparisonAbout UNH UnitedHealth Group
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2025. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to affiliates and third parties.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.